Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06616766 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
A Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer), sponsored by Yuhan Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 161
- Enrollment target
- 8
- Study locations
NCT06616766: Recruiting Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer), sponsored by Yuhan Corporation.
NCT06616766 is a Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer) that is actively recruiting participants, run by Yuhan Corporation. The registered enrollment target is 161 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (27% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06616766, a Phase 1 study of Solid Tumor and NSCLC (Non-small Cell Lung Cancer), is actively recruiting participants, sponsored by Yuhan Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 161 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
Primary Outcome
To assess the safety and tolerability of YH42946
Conditions Studied
Interventions
- DRUG YH42946
Study Locations (8)
Other
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University - Seoul
- Samsung Medical Center - Seoul
- Asan Medical Center, University of Ulsan - Seoul
Gyeonggi-do
- Seoul National University Bundang Hospital - Seongnam-si
- The Catholic Univ. of Korea St. Vincent's Hospital - Suwon
Virginia
- Next Oncology Virginia - Fairfax
North Chungcheong
- Chungbuk National University Hospital - Cheongju-si
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2028-07-29 |
| Phase | Phase 1 |
What NCT06616766 shows while recruiting
NCT06616766 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which YH42946 is the first listed.
NCT06616766 lists 8 locations in 4 states (Other, Gyeonggi-do, Virginia).
Frequently Asked Questions
What is clinical trial NCT06616766 about?
NCT06616766 is a clinical study titled "A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946". The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
What is the current status of trial NCT06616766?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 161 participants. The study started on 2024-10-02. Estimated completion is 2028-07-29.
What conditions does trial NCT06616766 study?
This clinical trial studies the following conditions: Solid Tumor, NSCLC (Non-small Cell Lung Cancer).
What interventions are being tested in trial NCT06616766?
The interventions under investigation include: YH42946 (DRUG).
Who is sponsoring clinical trial NCT06616766?
This trial is sponsored by Yuhan Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06616766 being conducted?
This trial has 8 study locations across Virginia, Gyeonggi-do, North Chungcheong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06616766's enrollment target sits among peer trials
161 54th of 196 higher than 143 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT07144826 · 161 participants · Early Phase 1
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI